← Leaderboards
Ashley Hall Shoemaker
Vanderbilt University Medical Center
$4,371,516
Attributed
$4,552,141
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $886.7K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,552,141 · 4
By mechanism
R01$3,604,616 · 2
K23$777,525 · 1
R03$170,000 · 1
Top collaborators
- Joan Christine Han1 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Yingchang Lu$6,135,479
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionMutationChildObesityPseudohypoparathyroidismHypothalamic StructureHormone ResistanceNon-Insulin-Dependent Diabetes MellitusImpairmentGtp-Binding ProteinsPhenotypeClinical TrialsThyroid GlandCoupledReceptorClinical ResearchG-Protein-Coupled ReceptorsFundingRare DiseasesChildhoodGtp-Binding Protein Alpha Subunits, GsEnergy MetabolismMelanocortin 4 ReceptorGenetic Diseases
Grant awards (15)
Phase 2 Study of Theophylline for the Treatment of Psuedohypoparathyroidism$363,169
R01 · FY2025 · DK · contact PI
Targeting BDNF Using Atomoxetine for the Treatment of Obesity Caused by MC4R Insufficiency$361,250
R01 · FY2025 · DK
Phase 2 Study of Theophylline for the Treatment of Psuedohypoparathyroidism$845,394
R01 · FY2024 · DK · contact PI
Phase 2 Study of Theophylline for the Treatment of Psuedohypoparathyroidism$670,316
R01 · FY2023 · DK · contact PI
Phase 2 Study of Theophylline for the Treatment of Psuedohypoparathyroidism$216,354
R01 · FY2023 · DK · contact PI
Phase 2 Study of Theophylline for the Treatment of Psuedohypoparathyroidism$670,316
R01 · FY2022 · DK · contact PI
Phase 2 Study of Theophylline for the Treatment of Psuedohypoparathyroidism$477,817
R01 · FY2021 · DK · contact PI
Glucose Homeostasis and Beta Cell Function in Pseudohypoparathyroidism$85,000
R03 · FY2020 · DK · contact PI
Glucose Homeostasis and Beta Cell Function in Pseudohypoparathyroidism$85,000
R03 · FY2019 · DK · contact PI
Early Onset Obesity and Cognitive Impairment in Pseudohypoparathyroidism$162,248
K23 · FY2018 · DK · contact PI
Early Onset Obesity and Cognitive Impairment in Pseudohypoparathyroidism$163,048
K23 · FY2017 · DK · contact PI
Early Onset Obesity and Cognitive Impairment in Pseudohypoparathyroidism$153,852
K23 · FY2016 · DK · contact PI
Early Onset Obesity and Cognitive Impairment in Pseudohypoparathyroidism$101,391
K23 · FY2015 · DK · contact PI
Early Onset Obesity and Cognitive Impairment in Pseudohypoparathyroidism$52,461
K23 · FY2015 · DK · contact PI
Early Onset Obesity and Cognitive Impairment in Pseudohypoparathyroidism$144,525
K23 · FY2014 · DK · contact PI